PTN Key Statistics, Chart & Performance
The current stock price of PTN is 16.31 USD. In the past month the price decreased by -4.34%. In the past year, price increased by 842.78%.
PTN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PTN. When comparing the yearly performance of all stocks, PTN is one of the better performing stocks in the market, outperforming 99.98% of all stocks.
PTN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PTN. PTN may be in some trouble as it scores bad on both profitability and health.
PTN Financial Highlights
Over the last trailing twelve months PTN reported a non-GAAP Earnings per Share(EPS) of -59.5. The EPS increased by 52.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -625.34% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PTN Forecast & Estimates
7 analysts have analysed PTN and the average price target is 55.42 USD. This implies a price increase of 239.79% is expected in the next year compared to the current price of 16.31.
For the next year, analysts expect an EPS growth of 99.03% and a revenue growth -100% for PTN
PTN Ownership
PTN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.87 | 382.02B | ||
| AMGN | AMGEN INC | 15.71 | 185.02B | ||
| GILD | GILEAD SCIENCES INC | 15.76 | 160.18B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.56 | 117.00B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.65 | 78.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 716.59 | 48.28B | ||
| INSM | INSMED INC | N/A | 33.34B | ||
| NTRA | NATERA INC | N/A | 33.51B | ||
| BIIB | BIOGEN INC | 10.31 | 25.32B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.72B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.8 | 20.23B | ||
| INCY | INCYTE CORP | 16.3 | 20.55B |
Related stock screener links
About PTN
Company Profile
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. The company is headquartered in Cranbury, New Jersey and currently employs 29 full-time employees. The firm is developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. The melanocortin receptor (MCr) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The firm's product development activities are focused on obesity, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity; ocular indications, including PL9643, an ophthalmic peptide solution for dry eye disease (DED), and ulcerative colitis, including PL8177, an oral peptide formulation. Its pipeline also includes PL7737 and PL9588. The firm's PL9588 is being developed as a topical treatment for glaucoma.
Company Info
PALATIN TECHNOLOGIES INC
4-B Cedar Brook Drive, Cedar Brook Corporate Center
Cranbury NEW JERSEY 08512 US
CEO: Carl Spana
Employees: 29
Phone: 16094952200
PALATIN TECHNOLOGIES INC / PTN FAQ
What does PTN do?
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. The company is headquartered in Cranbury, New Jersey and currently employs 29 full-time employees. The firm is developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. The melanocortin receptor (MCr) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The firm's product development activities are focused on obesity, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity; ocular indications, including PL9643, an ophthalmic peptide solution for dry eye disease (DED), and ulcerative colitis, including PL8177, an oral peptide formulation. Its pipeline also includes PL7737 and PL9588. The firm's PL9588 is being developed as a topical treatment for glaucoma.
What is the current price of PTN stock?
The current stock price of PTN is 16.31 USD. The price decreased by -2.97% in the last trading session.
What is the dividend status of PALATIN TECHNOLOGIES INC?
PTN does not pay a dividend.
What is the ChartMill rating of PALATIN TECHNOLOGIES INC stock?
PTN has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is PALATIN TECHNOLOGIES INC (PTN) stock traded?
PTN stock is listed on the NYSE Arca exchange.
What do analysts say about PALATIN TECHNOLOGIES INC (PTN) stock?
7 analysts have analysed PTN and the average price target is 55.42 USD. This implies a price increase of 239.79% is expected in the next year compared to the current price of 16.31.
What is the employee count for PTN stock?
PALATIN TECHNOLOGIES INC (PTN) currently has 29 employees.